




ASX Spotlight Presentation

November 25, 2009

Company Profile

Introduction



- Emerging leader for innovative safety medical devices
- Core focus on safety syringes
- ISO-13485 certified, FDA-registered facilities in PA
- Building a world-class team
- Strong alliances with global healthcare and pharma leaders

Company Profile

Financial Snapshot



- ASX listed (UNI) since 2002
- 8000 shareholders
- Shares on issue 307.8 million
- Market capitalization A\$310m
- A\$55.7 million cash balance
- 2008/09 revenue of \$40m
- 2008/09 After tax profit \$12m

The Global Transition to Safety Syringes



- 35 billion syringes used a year+
- 1.3 million deaths per year from unsafe injection practices*
 - Needlestick injuries
 - Reuse, sharing and disposal
- US mandates safety devices that can prevent needlestick injuries^
- EU & other markets now following

+ International Association of Safe Injection Technologies (2004)


* World Health Organization

^ Federal Needlestick Prevention Act (2000), Enforcement by OSHA (Bloodborne Pathogens Standard)

Unilife Brand Architecture


Core Safety Syringe Technology

- Automatic needle retraction
- Operator-controlled withdrawal
- Auto-Disable
- Fully integrated



UNI TRACT ™
Sharps Safety Devices

Plastic for vial



UNIFILL 

Glass ready-to-fill



Pharmaceutical Market for Prefilled Syringes



- 50+ drugs in prefilled format
- 3B prefilled syringes by 2012
- High entry barriers, few suppliers
- No prefilled with integrated safety
- Use of ancillary safety products
 - Production & shipment costs
 - Size hinders marketability

Unifill™ syringe

Key Industrial Advantages



- Fully integrated medical device
- Compatible with standard filling and packaging systems
- Supplied as per standard handling
- 60% reduction packaging volume
- Reduced transport costs

Unifill™ syringe

Key Marketing Advantages



- Compliant with legislation
- Strong market differentiation
- Minimal operator retraining
- Ideal for self-administration
- Convenient waste disposal

Comparisons to Ancillary Safety Products



Ancillary Safety Products


Unifill™ syringe

Attached onto Standard Prefilled Syringes

Unifill™ syringe

Industrialisation Program

- Program started July 2008
- 1-year ahead of schedule
- Completion in late-2010
- Engagement of Mikron
- Aggressive ramp plan



* Prefilled Syringe Market Growth 2009- 2012 estimated by Greystone Associates. Prefilled Syringes, May 2009. (Average annual growth trend beyond 2012 continued to 2016)


Relationship with sanofi-aventis

A\$46m to develop Unifill™, negotiate its purchase

- Signed Exclusive Agreement in June 2008
 - Payment of A\$16.4m (€10m) on signing of Exclusive Agreement
 - Industrialisation program with quarterly milestone payments
 - Milestone payments of €11.5m to date (€5.5m still to come)
- Signed Industrialisation Agreement in July 2009
 - Committed to fund industrialisation program A\$30.4m (€17m)
 - Retained right to sell to other customers in therapeutic classes to be agreed by both parties

Additional market opportunities

Indicative Pharmaceutical Share of Key Prefilled Therapeutic Markets



Calculated by published average unit cost per dose of 50 drugs available in a prefilled syringe format where 2008 annual revenues have been disclosed by the pharmaceutical company.

Note - some drugs are available in formats other than a prefilled syringe. Unilife has used available industry data and its own estimates to calculate the % of doses supplied in a prefilled syringe format. The cost / unit of some drugs vary depending upon the measured dosage.

Unitract™ Range of 1mL Syringes



- Target markets include:
 - Healthcare facilities
 - Diabetes / home-injection
 - Harm reduction
- Insulin, TB and Safe variants
- FDA and CE Mark certified
- US-production began Aug 2009

Product Pipeline

- Developing full range of plastic & glass syringes
- Unitract™ Clinical Range
 - 3mL and 5mL
 - Standard luer needles
- Unifill™ Select
 - Attachable needles



Key Upcoming Milestones

- Commercial release of US-made Unitract™ 1mL syringes
- Completion of negotiations for Unifill™ exclusivity list
- Redomiciliation and listing on NASDAQ
- Open new global headquarters and production facility in PA
- Installation of Unifill™ commercial assembly line
- Completion of Unifill™ industrialisation program
- Agreements with additional pharmaceutical companies

Summary

- US-based and (soon-to-be) NASDAQ listed business
- World-class team with strong industry credentials
- ISO-13485 certified with FDA-registered production facilities
- Unifill™ syringe represents ‘disruptive technology’
- Largest prefilled purchaser funding industrialisation program
- Strong cash position, multiple funding & revenue streams
- Target revenues of A\$400m+ beyond 2014